Literature DB >> 30871273

Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity.

Ishita Gupta1, Rasha M Sareyeldin2, Israa Al-Hashimi3, Hamda A Al-Thawadi4, Halema Al Farsi5, Semir Vranic6, Ala-Eddin Al Moustafa7,8.   

Abstract

Breast cancer is the most frequent cause of cancer-related deaths among women worldwide. It is classified into four major molecular subtypes. Triple-negative breast cancers (TNBCs), a subgroup of breast cancer, are defined by the absence of estrogen and progesterone receptors and the lack of HER-2 expression; this subgroup accounts for ~15% of all breast cancers and exhibits the most aggressive metastatic behavior. Currently, very limited targeted therapies exist for the treatment of patients with TNBCs. On the other hand, it is important to highlight that knowledge of the molecular biology of breast cancer has recently changed the decision-making process regarding the course of cancer therapies. Thus, a number of new techniques, such as gene profiling and sequencing, proteomics, and microRNA analysis have been used to explore human breast carcinogenesis and metastasis including TNBC, which consequently could lead to new therapies. Nevertheless, based on evidence thus far, genomics profiles (gene and miRNA) can differ from one geographic location to another as well as in different ethnic groups. This review provides a comprehensive and updated information on the genomics profile alterations associated with TNBC pathogenesis associated with different ethnic backgrounds.

Entities:  

Keywords:  biomarkers; breast cancer; gene expression profiling; miRNA; microarray; triple negative breast cancer

Year:  2019        PMID: 30871273      PMCID: PMC6468678          DOI: 10.3390/cancers11030363

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  14 in total

1.  LacdiNAcylation of N-glycans in MDA-MB-231 human breast cancer cells results in changes in morphological appearance and adhesive properties of the cells.

Authors:  Kiyoko Hirano; Yoshio Takada; Kiyoshi Furukawa
Journal:  Histochem Cell Biol       Date:  2019-10-12       Impact factor: 4.304

2.  Expression of glucose-regulated protein 78 as prognostic biomarkers for triple-negative breast cancer.

Authors:  Chenlian Yang; Zhiwei Zhang; Yutian Zou; Guanfeng Gao; Lingrui Liu; Haifan Xu; Feng Liu
Journal:  Histol Histopathol       Date:  2019-11-19       Impact factor: 2.303

3.  Occupational exposure to volatile organic compounds affects microRNA profiling: Towards the identification of novel biomarkers.

Authors:  Renata Sisto; Pasquale Capone; Luigi Cerini; Enrico Paci; Daniela Pigini; Monica Gherardi; Andrea Gordiani; Nunziata L'Episcopo; Giovanna Tranfo; Pieranna Chiarella
Journal:  Toxicol Rep       Date:  2020-06-03

Review 4.  MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer.

Authors:  Lei Ding; Huan Gu; Xianhui Xiong; Hongshun Ao; Jiaqi Cao; Wen Lin; Min Yu; Jie Lin; Qinghua Cui
Journal:  Cells       Date:  2019-11-22       Impact factor: 6.600

Review 5.  Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets.

Authors:  Ishita Gupta; Balsam Rizeq; Semir Vranic; Ala-Eddin Al Moustafa; Halema Al Farsi
Journal:  Int J Mol Sci       Date:  2020-09-15       Impact factor: 5.923

Review 6.  The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis.

Authors:  Haomeng Zhang; Jiao Wang; Yulong Yin; Qingjie Meng; Yonggang Lyu
Journal:  Biosci Rep       Date:  2021-02-26       Impact factor: 3.840

7.  MicroRNA-598 inhibits the growth of triple negative breast cancer cells by targeting JAG1.

Authors:  Guohui Han; Xiangdong Bai; Hongchuan Jiang; Qiang He
Journal:  Exp Ther Med       Date:  2021-01-21       Impact factor: 2.447

8.  The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.

Authors:  Xiaying Zheng; Mengge Huang; Lei Xing; Rui Yang; Xiaosong Wang; Rong Jiang; Luyu Zhang; Junxia Chen
Journal:  Mol Cancer       Date:  2020-04-07       Impact factor: 27.401

9.  Deep graph embedding for prioritizing synergistic anticancer drug combinations.

Authors:  Peiran Jiang; Shujun Huang; Zhenyuan Fu; Zexuan Sun; Ted M Lakowski; Pingzhao Hu
Journal:  Comput Struct Biotechnol J       Date:  2020-02-15       Impact factor: 7.271

10.  RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis.

Authors:  Hiroko Toda; Naohiko Seki; Sasagu Kurozumi; Yoshiaki Shinden; Yasutaka Yamada; Nijiro Nohata; Shogo Moriya; Tetsuya Idichi; Kosei Maemura; Takaaki Fujii; Jun Horiguchi; Yuko Kijima; Shoji Natsugoe
Journal:  Mol Oncol       Date:  2019-12-29       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.